​

CytomX Therapeutics (CTMX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CTMX Stock Forecast

CytomX Therapeutics (CTMX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $10.71, with a high of $16.00 and a low of $6.00. This represents a 268.04% increase from the last price of $2.91.

- $4 $8 $12 $16 $20 High: $16 Avg: $10.71 Low: $6 Last Closed Price: $2.91

CTMX Stock Rating

CytomX Therapeutics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (80.95%), 4 Hold (19.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 4 17 0 Strong Sell Sell Hold Buy Strong Buy

CTMX Price Target Upside V Benchmarks

TypeNameUpside
StockCytomX Therapeutics268.04%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1411
Avg Price Target$6.00$11.25$9.05
Last Closing Price$2.91$2.91$2.91
Upside/Downside106.19%286.60%211.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2636---9
May, 2636---9
Apr, 2636---9
Mar, 26252--9
Feb, 26252--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 19, 2026Wolfe Research$6.00$3.5071.43%106.19%
May 11, 2026H.C. Wainwright$11.00$3.98176.38%278.01%
Mar 18, 2026Roger SongJefferies$16.00$4.61247.07%449.83%
Mar 16, 2026Matthew BieglerOppenheimer$12.00$8.0349.44%312.37%
Feb 04, 2026Barclays$10.00$6.0764.74%243.64%
Jan 20, 2026Piper Sandler$10.00$5.3985.53%243.64%
Jan 20, 2026Michael SchmidtGuggenheim$10.00$5.3985.53%243.64%
Jan 20, 2026Etzer DaroutBarclays$8.00$5.3948.42%174.91%
Oct 21, 2025Etzer DaroutBarclays$6.00$3.7460.43%106.19%
Sep 16, 2025Etzer DaroutBarclays$3.50$1.9678.57%20.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 19, 2026Wolfe ResearchOutperforminitialise
Mar 18, 2026JefferiesBuyBuyhold
Mar 16, 2026OppenheimerOutperformOutperformhold
Jan 20, 2026Piper SandlerOverweightOverweighthold
Jan 20, 2026GuggenheimBuyinitialise
Jan 20, 2026BarclaysOverweightOverweighthold
Oct 21, 2025BarclaysOverweightOverweighthold
Oct 14, 2025OppenheimerOutperformOutperformhold
Sep 22, 2025Cantor FitzgeraldOverweightinitialise
Aug 13, 2025BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.26$-1.48$-0.01$0.38$-0.15---
Avg Forecast$-1.26$-1.29$-0.07$-0.04$-0.46$-0.74$-0.77$-0.60
High Forecast$-0.73$-0.58$0.70$0.12$-0.16$-0.50$-0.56$-0.19
Low Forecast$-1.61$-1.93$-0.77$-0.32$-0.70$-1.06$-1.07$-1.02
Surprise %-14.73%-85.71%-1050.00%-67.39%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$37.31M$53.16M$101.21M$138.10M$76.20M---
Avg Forecast$69.41M$72.04M$94.20M$115.66M$80.53M$39.30M$29.31M$61.12M
High Forecast$84.24M$99.74M$101.65M$133.01M$117.49M$60.66M$45.23M$94.34M
Low Forecast$47.10M$41.63M$86.17M$84.70M$44.50M$18.61M$13.88M$28.94M
Surprise %-46.25%-26.21%7.44%19.40%-5.38%---

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-115.87M$-99.32M$-569.00K$31.87M$-20.37M---
Avg Forecast$-93.13M$-89.43M$-569.00K$-7.55M$-32.13M$-75.82M$-60.17M$-43.92M
High Forecast$-54.21M$-71.54M$-455.20K$8.81M$-11.64M$-36.64M$-41.17M$-13.86M
Low Forecast$-118.99M$-107.31M$-682.80K$-23.92M$-51.40M$-78.28M$-79.17M$-74.94M
Surprise %24.41%11.06%--521.87%-36.60%---

CTMX Forecast FAQ

Is CytomX Therapeutics stock a buy?

CytomX Therapeutics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CytomX Therapeutics is a favorable investment for most analysts.

What is CytomX Therapeutics's price target?

CytomX Therapeutics's price target, set by 21 Wall Street analysts, averages $10.71 over the next 12 months. The price target range spans from $6 at the low end to $16 at the high end, suggesting a potential 268.04% change from the previous closing price of $2.91.

How does CytomX Therapeutics stock forecast compare to its benchmarks?

CytomX Therapeutics's stock forecast shows a 268.04% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CytomX Therapeutics over the past three months?

  • June 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is CytomX Therapeutics’s EPS forecast?

CytomX Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.74, marking a 393.33% increase from the reported $-0.15 in 2025. Estimates for the following years are $-0.77 in 2027, and $-0.6 in 2028.

What is CytomX Therapeutics’s revenue forecast?

CytomX Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $39.3M, reflecting a -48.43% decrease from the reported $76.2M in 2025. The forecast for 2027 is $29.31M, and $61.12M for 2028.

What is CytomX Therapeutics’s net income forecast?

CytomX Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-75.821M, representing an 272.22% increase from the reported $-20.37M in 2025. Projections indicate $-60.173M in 2027, and $-43.916M in 2028.